Ocular Therapeutix tumbles 18.8% on rival Kodiak's trial win
Kodiak Sciences' experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage wet AMD trial. RBC Capital Markets said the selloff in Ocular Therapeutics was overdone.
Kodiak Sciences' experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage wet AMD trial. RBC Capital Markets said the selloff in Ocular Therapeutics was overdone.